Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Clin Cancer Res. 2021 Sep 2;27(23):6467–6478. doi: 10.1158/1078-0432.CCR-21-0544

Figure 5.

Figure 5.

Evaluation of [18F]DASA-23 in GBM patient IC-2. A Representative contrast-enhanced T1-weighted MRI shown in the coronal plane. B Representative 30-60 min summed [18F]DASA-23 PET shows high uptake of the radiotracer in the area corresponding to contrast enhancement. C Fused 30-60 min summed [18F]DASA-23 PET/MRI. Yellow arrows indicate the location of the tumor. H&E staining (D) and PKM2 IHC (E) of the biopsied tissue shown at 0.4×, scale bar indicates 4mm. H&E (F) and PKM2 IHC (G) of the area shown within the black box in the insert confirm the expression of PKM2 within the malignant cells, images are shown at 10× and scale bar represents 300 μm.